Trials / Completed
CompletedNCT01306929
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Prilenia · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pridopidine | 45mg bid |
Timeline
- Start date
- 2011-03-24
- Primary completion
- 2018-01-05
- Completion
- 2018-01-05
- First posted
- 2011-03-02
- Last updated
- 2022-02-09
- Results posted
- 2022-02-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01306929. Inclusion in this directory is not an endorsement.